RM-2

Summary

Rm-2 (CHEMBL4301788) is a phase-3 clinical-stage unknown targeting GRPR.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 1 (GRPR)

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4301788
Name	RM-2
Type	Unknown
Max phase	3

Parent form; salt/anhydrous children: CHEMBL4297341

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GRPR	BB2 receptor	Antagonist	8.1	0%	P30550

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GRPR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	1	GRPR
G alpha (q) signalling events	1	GRPR

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
learning or memory	1
social behavior	1
psychomotor behavior	1
regulation of cell population proliferation	1
response to external biotic stimulus	1
motor behavior	1
positive regulation of respiratory gaseous exchange	1
positive regulation of behavioral fear response	1
signal transduction	1
neuropeptide signaling pathway	1

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).